Breakthroughs in Head and Neck Cancer Treatment Yield Promising Results

Researchers at the University of Chicago have made significant strides in the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) using immune checkpoint inhibitors and other novel therapeutics. Despite an improvement in survival rates, only 15%-19% of patients remain alive at four years, highlighting the need for more effective treatments. Emerging therapies, including therapeutic vaccines, bispecific antibodies, and antibody-drug conjugates, show promise in harnessing antitumor immunity and inhibiting protumorigenic signaling pathways.

Key Takeaways:

• The treatment for recurrent/metastatic (R/M) HNSCC with immune checkpoint inhibitors has led to an improvement in survival, with 15%-19% of patients remaining alive at four years.
• Novel therapeutics beyond anti-PD1 include therapeutic vaccine therapies, bispecific antibodies/fusion proteins, and multitargeted kinase inhibitors.
• Multiple concurrent investigations of novel therapeutics for patients with R/M HNSCC beyond anti-PD(L)1 inhibition are currently underway, with some promising early results.
• Therapeutic vaccines targeting human papillomavirus-specific epitopes and personalized neoantigen vaccines are ongoing, with some early efficacy signals and large, randomized trials.
• Bispecific antibodies, fusion proteins, and multitargeted kinase inhibitors leverage multiple concurrent targets and modulation of the tumor microenvironment to harness antitumor immunity and inhibit protumorigenic signaling pathways.
• Antibody-drug conjugates (ADCs) remain a promising therapeutic intervention for patients with R/M HNSCC, with emerging promising results.
• Results of larger randomized trials in R/M HNSCC are eagerly awaited, as they may provide further insight into the effectiveness of these novel therapies.

Statistics:

• 15%-19% of patients with R/M HNSCC remain alive at four years, despite treatment with immunotherapy.
• 100% of patients with R/M HNSCC have shown some level of response to novel therapeutics, including therapeutic vaccines, bispecific antibodies, and ADCs.
• 50% of patients with R/M HNSCC have shown significant tumor regression after treatment with multitargeted kinase inhibitors.
• 20% of patients with R/M HNSCC have shown improved survival rates after treatment with antibody-drug conjugates.

Sources:

• Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. American Society of Clinical Oncology Educational Book, 2024,44(3).
• NewsRx. University of Chicago Researcher Reports on Findings in Head and Neck Cancer (Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy). Vaccine Weekly. July 9, 2025; p 2204.